Regulatory milestones

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.14 to $4.47 last week after the European Commission approved an MAA for Adasuve Staccato to treat mild to moderate agitation in adults with schizophrenia or bipolar disorder. Alexza's European commercialization partner Grupo Ferrer Internacional S.A. plans to launch the product in 3Q13.